HB2004, titled Tyler’s Law, would direct the Secretary of Health and Human Services to study how often hospital emergency departments test for fentanyl when treating overdose patients, along with the costs, benefits, and risks of such testing. The bill also requires the study to examine how fentanyl testing may affect patient experience, including privacy, confidentiality of health information, and the patient-physician relationship.
After the study is completed, HHS would have to issue guidance on whether emergency departments should make fentanyl testing a routine part of overdose care. That guidance would also address how hospitals can ensure clinicians know which substances are included in routine drug screens and how fentanyl testing may affect future overdose risk and broader health outcomes.
Impact
The bill does not itself mandate fentanyl testing in emergency departments or directly change clinical practice standards. Instead, it creates a federal research-and-guidance process under the Department of Health and Human Services, with findings that could influence hospital protocols, emergency medicine practices, and future federal or state policy related to overdose treatment and toxicology screening. It specifically references hospital emergency departments as defined under the Social Security Act, so the practical effect would be on hospitals, clinicians, and overdose patients nationwide.
Sentiment
The available context suggests generally favorable bipartisan sentiment. The bill was introduced with a broad coalition of House sponsors from both parties, and it was forwarded by subcommittee to the full committee by voice vote, indicating no recorded opposition in that stage. The absence of recorded votes or transcript debate also suggests the measure was treated as a relatively noncontroversial public health study and guidance bill.
Contention
The main issues the bill anticipates are not partisan but practical and clinical: whether routine fentanyl testing is useful, what it costs, whether it improves outcomes, and whether it could create privacy or trust concerns for patients. Potential points of contention include the burden on emergency departments, the reliability and usefulness of testing, and whether routine screening could affect the patient-physician relationship or confidentiality of personal health information. The bill’s supporters appear to be focused on improving overdose care and awareness of fentanyl exposure, while any concerns would likely come from hospital administrators, clinicians, or privacy advocates rather than from a clear ideological divide.
Controlled substances: other; definition of governmental agency under the administration of opioid antagonist act; modify. Amends sec. 101 of 2019 PA 39 (MCL 15.671). TIE BAR WITH: SB 404'25
Health occupations: pharmacists; dispensing certain addiction medications without undue delay; require. Amends 1978 PA 368 (MCL 333.1101 - 333.25211) by adding sec. 7333c.
Insurance: health insurers; prior authorization for certain opioid use disorder and alcohol use disorder medications; prohibit. Amends 1956 PA 218 (MCL 500.100 - 500.8302) by adding sec. 3406ww.
Human services: medical services; exemption of certain prescription drugs from the medical assistance prior authorization process; provide for. Amends sec. 109h of 1939 PA 280 (MCL 400.109h).
Controlled substances: other; opioid antagonist policy; require schools to implement in certain circumstances. Amends sec. 1178 of 1976 PA 451 (MCL 380.1178) & adds sec. 1179c. TIE BAR WITH: SB 405'25